News

Rising healthcare costs impact their own organization’s competitiveness, said those who responded to the Pulse of the Purchaser survey by the National Alliance of Healthcare Purchaser Coalitions.

The report from the American Medical Association evaluates health insurer market share at the metropolitan statistical area level and national level.

Mike Tuffin is set to become AHIP's President and CEO from January 8, 2024, succeeding Julie Simon Miller.

Joe Kvedar, M.D., the immediate past chair of the association, is chairing the 35-member group that will be focused on eliminating barriers to telehealth and other types of virtual health.

Researchers of a study compared Israel's CVOID-19 booster rollout experience to the United States to ask the question: How many lives could the U.S. have saved if boosters were authorized sooner?

Leaders and clinicians say they are seeing better patient outcomes and a good return on their investments, according to a recent survey.

The application deadline to serve on the committee is Dec. 11.

Pharmacy benefit managers have been under pressure to simplify their complicated, obscure pricing tactics.

The authors found that patients who received DAA treatment had a five-year survival rate of 47.2% compared with 35.2% for untreated patients.

Electronic health records often do not record when someone has died. The deceased continue to get a variety of healthcare reminders.

As of today, 40 states and Washington, D.C., have expanded their Medicaid programs under the Affordable Care Act.

Cigna has been looking to sell its Medicare Advantage business, perhaps as a way to fend off antitrust objection to the deal.

CTTP is rare hereditary blood clotting disorder stemming from a disease-causing mutation in the ADAMTS13 gene. This gene plays a crucial role in producing the ADAMTS13 enzyme, responsible for regulating blood clotting.

FDA has approved a new therapy for HR positive breast cancer and announces plan to hold advisory meeting for Abecma in earlier treatment of multiple myeloma. In addition, Janssen has submitted a supplemental application for Rybrevant in NSCLC.

Pfizer and BioNTech released positive top-line data for their mRNA-based combination vaccine that targets influenza and COVID-19.

Prior to the IRA, there were no limits on beneficiary OOP spending throughout the year. However, by 2025 the IRA will introduce the $2,000 maximum OOP expenses.

Healthcare leaders discussed digital health during the recent American Heart Association conference, outlining the potential and pitfalls. Often, setbacks aren’t related to the technology.

This is the latest offering by Express Scripts that aims to bring transparency to prescription drug costs.

Payers must be early adopters of managing genetic testing through DEX Z-Codes, combined with science-based policies and policy adherence and claims editing technology.

The Biden administration is looking at a policy change that would enable more older Americans to get oral and injectable medications.

Ejection fraction is a key factor in how clinicians diagnose, classify and treat heart failure. But you might not know it if you depended solely on ICD-10 codes.

First in class, biosimilars, oncology drugs and even some generics have been added to Optum Rx’s list of exclusions for 2024.

Researchers reported positive results at the AHA meeting today from a small, 48-patient study of lepodisiran, a short interfering RNA therapy designed to reduce lipoprotein(a) levels.

Ten patients have been treated with the CRISPR-based gene therapy, the drug developer's chief scientific officer announced today, and high doses have had the intended effect of lowering LDL cholesterol. One study volunteer died five weeks after the infusion from cardiac arrest, but the company says the death was unrelated to the therapy and no changes were made to the study.

A study that randomized villages in China to an intensive blood pressure-lowering program or usual care showed a 15% decrease in all-cause dementia from the program.

Healthcare researchers say it’s critical to get more women, Black and Latino participants in clinical trials. It can be done, but researchers and institutions must make the effort.

Several researchers point out that women face higher stress due to family duties, gender roles and social determinants. They say it’s an area worthy of more attention in research.

Positive findings from their placebo-controlled trial show that angioplasty is an evidence-based, first-line treatment for patients with stable angina and that they needn't necessarily be treated first with antianginal medications, say the ORBITA-2 investigators.